Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 38Myeloid 25Classical hematology 3Thoracic 2Lymphoid 2Dermatologic 2Breast 2Sarcoma 1Plasma cell 1Other solid neoplasm 1NET 1Head & Neck 1Genitourinary 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Melanoma 1Carcinoma, Merkel Cell 1

Interventions

pembrolizumab 326Nivolumab 289Ipilimumab 260Cyclophosphamide 194aldesleukin 145Interleukin-2 109fludarabine phosphate 107Temozolomide 83fludarabine 81Dacarbazine 81Radiotherapy 74trametinib 73Vemurafenib 69dabrafenib 66Biopsy 65sargramostim 50Bevacizumab 50Radiosurgery 49Paclitaxel 49Peripheral Blood Stem Cell Transplantation 48Magnetic Resonance Spectroscopy 48Carboplatin 48Imiquimod 47Aminolevulinic Acid 47binimetinib 45Cisplatin 45CTLA-4 Antigen 43cemiplimab 42atezolizumab 41Specimen Handling 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × decitabine and cedazuridine drug combination × Dermatologic × Clear all
NCT07472322 2026-05-29

ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1

University of Wisconsin, Madison

Phase 1/2 Not yet recruiting
31 enrolled
Dermatologic

Carcinoma, Merkel Cell

NCT05089370 2025-12-08

Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma

University of Colorado, Denver

Phase 1/2 Active not recruiting
8 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡